These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6092556)

  • 1. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.
    Harvey JH; Smith FP; Schein PS
    J Clin Oncol; 1984 Nov; 2(11):1245-8. PubMed ID: 6092556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
    Oster MW; Gray R; Panasci L; Perry MC
    Cancer; 1986 Jan; 57(1):29-33. PubMed ID: 2934124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage.
    Biran H; Sulkes A; Biran S
    Oncology; 1989; 46(2):83-7. PubMed ID: 2710481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer.
    Sakata Y; Komatsu Y; Takagi S; Saitoh S; Itoh T; Suzuki H; Tsushima K; Sasaki D; Yoshida Y
    Cancer Chemother Pharmacol; 1989; 23 Suppl():S9-12. PubMed ID: 2647315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Matsushiro T; Nimura Y; Nagakawa T; Nakayama T; Yamauchi H; Ogata Y; Shimada H; Miyakawa S; Yamaguchi A; Sakoda K; Yasuda H; Tsukada K; Yoshida K; Ashida H; Ishikawa Y; Kotoura Y; Kinoshita H; Kajiwara T; Watanabe G; Uchimura M; Funabiki T; Ikeda S; Okada S
    Gan To Kagaku Ryoho; 1996 May; 23(6):707-14. PubMed ID: 8645022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
    Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmed activity of FAM polychemotherapy in advanced gastric carcinoma.
    Fraschini P; Beretta G; Arnoldi E; Tedeschi L; Labianca R; Luporini G
    Tumori; 1983 Feb; 69(1):59-64. PubMed ID: 6687644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Kasimis BS; Moran EM; Miller JB; Forbes KA; Kaneshiro CA; Poblet MT; Williams JL
    Cancer Treat Rep; 1983 Oct; 67(10):937-9. PubMed ID: 6688755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
    Cullinan SA; Moertel CG; Fleming TR; Rubin JR; Krook JE; Everson LK; Windschitl HE; Twito DI; Marschke RF; Foley JF
    JAMA; 1985 Apr; 253(14):2061-7. PubMed ID: 2579257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
    Goldberg RM; Smith FP; Ueno W; Ahlgren JD; Schein PS
    J Clin Oncol; 1986 Mar; 4(3):395-9. PubMed ID: 3754004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of FAM regimen in 38 patients with advanced gastric cancer.
    Ridolfi R; Casadei Giunchi D; Cortesi C; Maltoni M; Ravaioli A; Amadori D
    Tumori; 1984 Aug; 70(4):375-9. PubMed ID: 6548054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin, and mitomycin C (FAM).
    Haim N; Cohen Y; Honigman J; Robinson E
    Cancer Chemother Pharmacol; 1982; 8(3):277-80. PubMed ID: 6897021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.
    Haller DG; Woolley PV; Macdonald JS; Smith LF; Schein PS
    Cancer Treat Rep; 1978 Apr; 62(4):563-5. PubMed ID: 350394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial.
    Takada T; Nimura Y; Katoh H; Nagakawa T; Nakayama T; Matsushiro T; Amano H; Wada K
    Hepatogastroenterology; 1998; 45(24):2020-6. PubMed ID: 9951857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas.
    Smith FP; Hoth DF; Levin B; Karlin DA; MacDonald JS; Woolley PV; Schein PS
    Cancer; 1980 Nov; 46(9):2014-8. PubMed ID: 7427908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
    J Clin Oncol; 1986 Dec; 4(12):1794-8. PubMed ID: 2946815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
    Cascinu S; Galizia E; Labianca R; Ferraù F; Pucci F; Silva RR; Luppi G; Beretta GD; Berardi R; Scartozzi M
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):37-43. PubMed ID: 20821330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.